RGNX - REGENXBIO Inc. Short-Term Debt to Capital

Graphic logo of REGENXBIO Inc. (RGNX)

The REGENXBIO Inc. (RGNX) price chart demonstrates the dynamics of an asset with an impeccable reputation in biomedicine due to the creation of unique gene delivery systems. REGENXBIO Inc. is developing the NAV platform to combat metabolic pathologies and vision loss, achieving a value of 0.46. The business relies on patent protection and successful trials, remaining independent of general economic fluctuations.

Ratio of Short-Term Indebtedness to Capital: REGENXBIO Inc (RGNX) for 07/04/2022 - 11/01/2026

RGNX (regenxbio.com): analytical breakdowns and indicator data

- stock value and consensus price forecast:
Price Chart Regenxbio|RGNX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization REGENXBIO Inc|RGNX - Enterprise Value
- book capitalization information:
Net Assets per Single Share REGENXBIO|RGNX - Accounting Value of Company|Market Capitalization to Book Value Ratio regenxbio.com|RGNX - Company Assets
- company liabilities and liquidity data:
Total Debt to Capital REGENXBIO Inc.|RGNX - Long-Term Indebtedness to Equity|Short-Term Debt to Capital REGENXBIO|RGNX - Company Cumulative Debt|Debt to Book Capitalization Ratio REGENXBIO Inc|RGNX - Company Long-Term Indebtedness|Company Current Liabilities REGENXBIO|Quick Ratio regenxbio.com
- company profitability and valuation multiples indicators:
RGNX - Company Net Income
Analysis of all company metrics:RGNX Regenxbio
Brand item of regenxbio.com

REGENXBIO Inc. (RGNX) minimizes strategic risks by outsourcing clinical trials to third-party contractors while maintaining full control over its patents. This indicator measures the company's reliance on short-term borrowings relative to its equity, determining its resilience to default. By analyzing changes in the share of short-term liabilities within the capital structure, an investor can identify the business's financial recovery phase. A decrease in this ratio confirms a conservative approach to liquidity management, although it may temporarily limit the overall return on assets.

Who REGENXBIO Inc. competes with

Short-Term Debt to Equity Tempus AI (TEM)|Qiagen Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IONS (Ionis Pharmaceuticals)|Short-Term Debt to Capital repligen.com RGEN|RNA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CRSP (CRISPR Therapeutics Inc)|WGS: Short-Term Debt to Capital|Current Liabilities to Capital Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc.) - Short-Term Debt to Capital|SRPT - Short-Term Indebtedness to Equity|Short-Term Debt to Capital TWST|TXG - Current Liabilities to Capital|Short-Term Debt to Equity Intellia NTLA|STOK: Short-Term Debt to Capital Ratio|BLFS: Short-Term Debt to Equity Ratio|WVE (wavelifesciences.com) - Short-Term Debt to Capital Ratio|MAZE: Short-Term Debt to Capital|SION (Sionna Therapeutics, Inc.) - Short-Term Debt to Equity|PRME (Prime Medicine Corp) - Short-Term Debt to Capital|Taysha Corp (TSHA) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity uniQure N.V. (QURE)|MGTX - Current Liabilities to Capital|Solid Biosciences - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OCGN|Pacific Biosciences of California - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Benitec Corp BNTC|Design Therapeutics (DSGN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio RCKT|FDMT (4D Molecular Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Lexeo (LXEO)|Short-Term Debt to Equity Ratio KRRO (Korro Bio, Inc.)|Short-Term Debt to Capital Coefficient Editas Corp|Short-Term Debt to Equity Silence Therapeutics SLN|Ratio of Short-Term Indebtedness to Capital PRQR|Codexis Bio - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Sangamo Therapeutics Inc. (SGMO)|nautilus.bio (NAUT) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio MGX|Short-Term Debt to Equity Ratio DTIL|Short-Term Debt to Capital Ratio GBIO (Generation Bio Corp)|Short-Term Debt to Capital BOLD|exicuretx.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Imunon IMNN|PHIO: Short-Term Debt to Capital Ratio|Mustang Bio Corp - Short-Term Debt to Capital|RNAZ - Short-Term Debt to Capital|bionanogenomics.com (BNGO) - Short-Term Debt to Equity|Applied DNA Sciences Inc - Ratio of Short-Term Indebtedness to Capital|BLUE (Bluebird Bio) - Short-Term Debt to Capital|Current Liabilities to Capital ImmunoPrecise IPA|Short-Term Debt to Capital OMGA|singulargenomics.com (OMIC) - Short-Term Indebtedness to Equity|Short-Term Debt to Capital RGLS (Regulus Therapeutics Inc.)|Syros Pharmaceuticals Inc. (SYRS) - Current Liabilities to Capital|TBIO - Short-Term Debt to Equity|TCON (TRACON Pharmaceuticals, Inc) - Short-Term Debt to Capital Ratio|UBX (Unity Biotechnology) - Short-Term Debt to Equity Ratio